2018 Q1 Form 10-Q Financial Statement
#000156459018013451 Filed on May 14, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| Revenue | $482.0K | $1.885M |
| YoY Change | -74.43% | |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.910M | $1.790M |
| YoY Change | 62.57% | -20.44% |
| % of Gross Profit | ||
| Research & Development | $6.690M | $1.070M |
| YoY Change | 525.23% | -82.18% |
| % of Gross Profit | ||
| Depreciation & Amortization | $72.00K | $18.00K |
| YoY Change | 300.0% | -90.53% |
| % of Gross Profit | ||
| Operating Expenses | $9.597M | $2.858M |
| YoY Change | 235.79% | -65.37% |
| Operating Profit | -$9.115M | -$973.0K |
| YoY Change | 836.79% | -88.21% |
| Interest Expense | $295.0K | $223.0K |
| YoY Change | 32.29% | 596.88% |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$8.710M | -$1.200M |
| YoY Change | 625.83% | -84.71% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$8.714M | -$1.200M |
| YoY Change | 626.17% | -84.72% |
| Net Earnings / Revenue | -1807.88% | -63.66% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$322.7K | -$5.714M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 71.59M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $49.30M | $17.60M |
| YoY Change | 180.11% | -53.68% |
| Cash & Equivalents | $49.28M | $2.940M |
| Short-Term Investments | $6.200M | |
| Other Short-Term Assets | $144.0K | $400.0K |
| YoY Change | -64.0% | -78.95% |
| Inventory | ||
| Prepaid Expenses | $1.477M | |
| Receivables | $4.000M | |
| Other Receivables | $0.00 | |
| Total Short-Term Assets | $54.90M | $20.00M |
| YoY Change | 174.5% | -50.74% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $4.300M | $0.00 |
| YoY Change | -100.0% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.400M | |
| YoY Change | ||
| Total Long-Term Assets | $32.30M | $0.00 |
| YoY Change | -100.0% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $54.90M | $20.00M |
| Total Long-Term Assets | $32.30M | $0.00 |
| Total Assets | $87.20M | $20.00M |
| YoY Change | 336.0% | -51.34% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.900M | $300.0K |
| YoY Change | 866.67% | -81.25% |
| Accrued Expenses | $2.800M | $1.900M |
| YoY Change | 47.37% | -52.5% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | |
| YoY Change | ||
| Total Short-Term Liabilities | $12.10M | $2.200M |
| YoY Change | 450.0% | -60.54% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $2.999M | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $828.0K | $2.400M |
| YoY Change | -65.5% | 50.0% |
| Total Long-Term Liabilities | $3.827M | $2.400M |
| YoY Change | 59.46% | 50.0% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $12.10M | $2.200M |
| Total Long-Term Liabilities | $3.827M | $2.400M |
| Total Liabilities | $16.30M | $4.600M |
| YoY Change | 254.35% | -35.92% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $70.94M | $15.30M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $87.20M | $20.00M |
| YoY Change | 336.0% | -51.28% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$8.714M | -$1.200M |
| YoY Change | 626.17% | -84.72% |
| Depreciation, Depletion And Amortization | $72.00K | $18.00K |
| YoY Change | 300.0% | -90.53% |
| Cash From Operating Activities | -$8.983M | -$2.650M |
| YoY Change | 238.98% | -75.07% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.719M | $8.000K |
| YoY Change | 21387.5% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | -$190.0K |
| YoY Change | -100.0% | -101.55% |
| Cash From Investing Activities | -$1.719M | -$200.0K |
| YoY Change | 759.5% | -101.63% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $7.000K | |
| YoY Change | -46.15% | |
| Debt Paid & Issued, Net | $3.605M | $600.0K |
| YoY Change | 500.83% | |
| Cash From Financing Activities | 1.067M | 4.070M |
| YoY Change | -73.78% | 40600.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -8.983M | -2.650M |
| Cash From Investing Activities | -1.719M | -200.0K |
| Cash From Financing Activities | 1.067M | 4.070M |
| Net Change In Cash | -9.635M | 1.220M |
| YoY Change | -889.75% | -24.69% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$8.983M | -$2.650M |
| Capital Expenditures | $1.719M | $8.000K |
| Free Cash Flow | -$10.70M | -$2.658M |
| YoY Change | 302.63% | -75.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
144000 | |
| CY2018Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1477000 | |
| CY2017Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1485000 | |
| CY2017Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
19000 | |
| CY2017Q4 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
0 | |
| CY2018Q1 | mtem |
In Process Research And Development
InProcessResearchAndDevelopment
|
26623000 | |
| CY2017Q4 | mtem |
In Process Research And Development
InProcessResearchAndDevelopment
|
26623000 | |
| CY2017Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
628000 | |
| CY2018Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | |
| CY2017Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
2400000 | |
| CY2018Q1 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
4000000 | |
| CY2018Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
98000 | |
| CY2017Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
70000 | |
| CY2018Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
2999000 | |
| CY2017Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
1078000 | |
| CY2018Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
828000 | |
| CY2018Q1 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
251000 | |
| CY2017Q1 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
125000 | |
| CY2018Q1 | us-gaap |
Revenues
Revenues
|
482000 | |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
1885000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
9597000 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2858000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9115000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-973000 | |
| CY2018Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
82000 | |
| CY2017Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
0 | |
| CY2018Q1 | us-gaap |
Interest Expense
InterestExpense
|
295000 | |
| CY2017Q1 | us-gaap |
Interest Expense
InterestExpense
|
223000 | |
| CY2018Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
614000 | |
| CY2017Q1 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
1000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8714000 | |
| CY2018Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
0 | |
| CY2017Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
427000 | |
| CY2018Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8714000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1622000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-7.56 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26989693 | |
| CY2018Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
27060035 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
26898330 | |
| CY2018Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
27060035 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
26898330 | |
| CY2018Q1 | mtem |
Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
|
231000 | |
| CY2017Q1 | mtem |
Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
|
1760000 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
214641 | |
| CY2018Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
0 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
0 | |
| CY2018Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-8714000 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1622000 | |
| CY2018Q1 | us-gaap |
Depreciation
Depreciation
|
72000 | |
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
18000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
643000 | |
| CY2018Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
63000 | |
| CY2017Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
38000 | |
| CY2017Q1 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
-2000 | |
| CY2018Q1 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
8000 | |
| CY2017Q1 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
0 | |
| CY2018Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-115000 | |
| CY2017Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
| CY2018Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-2000 | |
| CY2017Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
58000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-8000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
4000000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
750000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
71000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
0 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-355000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-139000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
110000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
473000 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
34000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
0 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
198000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
0 | |
| CY2018Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
3585000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-1135000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-8983000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-2654000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1719000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
8000 | |
| CY2018Q1 | us-gaap |
Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
|
0 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
|
188000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1719000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-196000 | |
| CY2018Q1 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
13000 | |
| CY2017Q1 | us-gaap |
Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
|
11000 | |
| CY2018Q1 | mtem |
Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
|
4537000 | |
| CY2017Q1 | mtem |
Proceeds From Issuance Of Long Term Debt And Warrants Net
ProceedsFromIssuanceOfLongTermDebtAndWarrantsNet
|
0 | |
| CY2018Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
3605000 | |
| CY2017Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
600000 | |
| CY2018Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
0 | |
| CY2017Q1 | us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
2685000 | |
| CY2018Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
148000 | |
| CY2017Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | |
| CY2018Q1 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
0 | |
| CY2017Q1 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
2000000 | |
| CY2018Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1067000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
4074000 | |
| CY2018Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-9635000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1224000 | |
| CY2017Q1 | mtem |
Non Cash Deemed Dividends On Preferred Stock
NonCashDeemedDividendsOnPreferredStock
|
428000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1716000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2940000 | |
| CY2018Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
51000 | |
| CY2017Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
68000 | |
| CY2018Q1 | mtem |
Non Cash Deemed Dividends On Preferred Stock
NonCashDeemedDividendsOnPreferredStock
|
0 | |
| CY2018Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain amounts in prior year’s presentations have been reclassified to conform to the current presentation. These classifications had no effect on previously reported net loss.</p></div> | |
| CY2018Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash, cash equivalents are with two major financial institutions in the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Takeda Pharmaceutical Company Ltd. (“Takeda”). Approximately 34% of total revenues for the three months ended March 31, 2018, were derived from Takeda. There was $4.0 million in accounts receivable due from Takeda at March 31, 2018 that was received in April 2018. See also Note 4, “Research and Development Agreements”, regarding the collaboration agreements with Takeda.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s drug candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p></div> | |
| CY2018Q1 | mtem |
Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
|
670000 | |
| CY2017Q4 | mtem |
Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
|
374000 | |
| CY2018Q1 | mtem |
Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
|
734000 | |
| CY2017Q4 | mtem |
Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
|
702000 | |
| CY2018Q1 | mtem |
Accrued Non Clinical Research Current
AccruedNonClinicalResearchCurrent
|
868000 | |
| CY2017Q4 | mtem |
Accrued Non Clinical Research Current
AccruedNonClinicalResearchCurrent
|
435000 | |
| CY2017Q3 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
11-for-1 reverse stock split | |
| CY2017Q3 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
11 | |
| CY2018Q1 | mtem |
Revenue Remaining Performance Obligation Expected Recognized Date
RevenueRemainingPerformanceObligationExpectedRecognizedDate
|
2019-06-30 | |
| CY2018Q1 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
5100000 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
0 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
0 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
0 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
0 | |
| CY2018Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2017Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2018Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
3000000 | |
| CY2017Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
3500000 | |
| CY2018Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
491000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1149000 | |
| CY2018Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
37000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
30000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
832000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
1135000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
1048000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
1074000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
1096000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
486000 | |
| CY2018Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
5671000 | |
| CY2018Q1 | us-gaap |
Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
41000 | |
| CY2018Q1 | us-gaap |
Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
|
33000 | |
| CY2018Q1 | us-gaap |
Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
|
19000 | |
| CY2018Q1 | us-gaap |
Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
|
93000 | |
| CY2018Q1 | us-gaap |
Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
|
7000 | |
| CY2018Q1 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
86000 | |
| CY2018Q1 | us-gaap |
Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
|
45000 | |
| CY2018Q1 | us-gaap |
Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
|
41000 | |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3331735 | |
| CY2018Q1 | mtem |
Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
|
190000 | |
| CY2018Q1 | mtem |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
0 | |
| CY2018Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
3521735 | |
| CY2018Q1 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0227 | |
| CY2017 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0189 | |
| CY2018Q1 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P1Y10M20D | |
| CY2017 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P2Y1M17D | |
| CY2018Q1 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2017 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0.00 | |
| CY2018Q1 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
0.89 | |
| CY2017 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
1.03 | |
| CY2018Q1 | us-gaap |
Share Price
SharePrice
|
8.00 | |
| CY2017Q4 | us-gaap |
Share Price
SharePrice
|
10.02 | |
| CY2018Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
643000 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
26000 | |
| CY2018Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
9200000 | |
| CY2018Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y4M24D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2768711 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
297750 | |
| CY2018Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
161705 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
24995 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2879761 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1470533 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.07 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
10.69 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.91 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
31.47 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.38 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
15.89 | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y7M6D | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y2M12D | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y10M24D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
11000000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
7700000 | |
| CY2018Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
6600000 | |
| CY2018Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1600000 | |
| CY2018Q1 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
|
0 |
